PMID- 29316197
OWN - NLM
STAT- MEDLINE
DCOM- 20190114
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Print)
IS  - 1462-8902 (Linking)
VI  - 20
IP  - 5
DP  - 2018 May
TI  - Tofogliflozin decreases body fat mass and improves peripheral insulin resistance.
PG  - 1311-1315
LID - 10.1111/dom.13211 [doi]
AB  - The impact of tofogliflozin, a sodium-glucose co-transporter-2 inhibitor, on 
      peripheral glucose uptake in patients with type 2 diabetes mellitus (T2DM) was 
      investigated using the hyperinsulinaemic-euglycaemic clamp method in a 
      single-arm, open-label study. The following variables were compared between 
      before and after tofogliflozin administration for 12 weeks in 16 patients with 
      T2DM who were receiving dipeptidyl peptidase-4 inhibitor treatment: body weight 
      (BW); blood pressure; glucose metabolism; liver function; lipid profile; and body 
      composition. Peripheral glucose uptake (M value and M/I ratio) was examined by 
      the hyperinsulinaemic-euglycaemic clamp method. After 12 weeks, there was a 
      significant decrease (P < .001) in glycated haemoglobin, BW, body fat mass and 
      lean body mass. Peripheral glucose uptake, which indicates insulin sensitivity, 
      increased significantly (M value by 0.90 and M/I ratio by 0.49; both P < .05). 
      The change in the M value after 12 weeks of tofogliflozin therapy was correlated 
      with the change in body fat mass (P < .05). Tofogliflozin significantly improved 
      insulin sensitivity and peripheral glucose uptake in patients with T2DM. These 
      improvements were significantly correlated with reduction in body fat mass.
CI  - (c) 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & 
      Sons Ltd.
FAU - Matsuba, Ren
AU  - Matsuba R
AUID- ORCID: 0000-0001-5041-6344
AD  - Department of Internal Medicine, Division of Metabolism and Endocrinology, St 
      Marianna University School of Medicine, Kanagawa, Japan.
FAU - Matsuba, Ikuro
AU  - Matsuba I
AD  - Matsuba Medical Clinic, Kanagawa, Japan.
FAU - Shimokawa, Mototsugu
AU  - Shimokawa M
AD  - Department of Cancer Information Research, National Kyushu Cancer Center, 
      Clinical Research Institute, Fukuoka, Japan.
FAU - Nagai, Yoshio
AU  - Nagai Y
AD  - Department of Internal Medicine, Division of Metabolism and Endocrinology, St 
      Marianna University School of Medicine, Kanagawa, Japan.
FAU - Tanaka, Yasushi
AU  - Tanaka Y
AD  - Department of Internal Medicine, Division of Metabolism and Endocrinology, St 
      Marianna University School of Medicine, Kanagawa, Japan.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180204
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Anti-Obesity Agents)
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (hemoglobin A1c protein, human)
RN  - P8DD8KX4O4 
      (6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol)
SB  - IM
MH  - Adiposity/*drug effects
MH  - Anti-Obesity Agents/adverse effects/*therapeutic use
MH  - Benzhydryl Compounds/adverse effects/*therapeutic use
MH  - Biomarkers/blood
MH  - Blood Glucose/analysis
MH  - Body Mass Index
MH  - Diabetes Mellitus, Type 2/blood/complications/*drug therapy/metabolism
MH  - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Drug Therapy, Combination/adverse effects
MH  - Electric Impedance
MH  - Glucose Clamp Technique
MH  - Glucosides/adverse effects/*therapeutic use
MH  - Glycated Hemoglobin/analysis
MH  - Hyperglycemia/*prevention & control
MH  - Hypoglycemia/chemically induced/prevention & control
MH  - *Insulin Resistance
MH  - Overweight/blood/complications/drug therapy/metabolism
MH  - Sodium-Glucose Transporter 2 Inhibitors/adverse effects/*therapeutic use
MH  - Weight Loss/drug effects
PMC - PMC5947308
OTO - NOTNLM
OT  - DPP-4 inhibitor
OT  - body composition
OT  - insulin resistance
OT  - type 2 diabetes
COIS- This research received financial support from Kowa Company Ltd, but was planned 
      and designed by the investigators. The company was not involved in the study 
      design, patient enrolment, data aggregation and analysis, data interpretation, or 
      preparation of this report.
EDAT- 2018/01/10 06:00
MHDA- 2019/01/15 06:00
PMCR- 2018/05/11
CRDT- 2018/01/10 06:00
PHST- 2017/09/15 00:00 [received]
PHST- 2017/12/24 00:00 [revised]
PHST- 2018/01/02 00:00 [accepted]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2019/01/15 06:00 [medline]
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/05/11 00:00 [pmc-release]
AID - DOM13211 [pii]
AID - 10.1111/dom.13211 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2018 May;20(5):1311-1315. doi: 10.1111/dom.13211. Epub 2018 
      Feb 4.